Hepatitis C News and Research

Latest Hepatitis C News and Research

WFA+-M2BP levels linked to liver fibrosis, HCC progression in chronic HBV

Japanese researchers have found that serum levels of glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein are a useful marker of not only the degree of liver fibrosis, but also progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection.

27 Apr 2016

Serum marker may flag liver fibrosis in chronic HBV

Serum levels of Wisteria floribunda agglutinin-positive Mac-2-binding protein may reflect the severity of liver fibrosis in patients with chronic hepatitis B virus infection, say researchers.

27 Apr 2016

Regular aspirin use may help reduce risk of bile duct cancer

Regular use of aspirin was linked with a significantly reduced risk of developing bile duct cancer, also called cholangiocarcinoma, in a recent study. The findings, which are published in the journal Hepatology, indicate that additional research on the potential of aspirin for preventing bile duct cancer is warranted.

27 Apr 2016

New blood treatment technology could reduce malaria risk following blood transfusions

Patients, especially children, who undergo blood transfusions in sub-Saharan Africa are at high risk of transfusion-transmitted malaria. A new trial, published in The Lancet today, suggests that treating donated blood with a new technology that combines UV radiation and vitamin B is safe and could minimise the risk of malaria infection following blood transfusions.

26 Apr 2016

Resolving HBV infection does not reduce liver cancer risk

Long-term infection with hepatitis B virus (HBV) can cause liver inflammation and increase the risk of liver cancer. Researchers from the US Centers for Disease Control and Prevention, however, found that resolving HBV infection was not associated with reduced rates of liver cancer.

25 Apr 2016

Johns Hopkins study suggests updated universal screening for hepatitis C virus

A review of blood samples for nearly 5,000 patients seen at The Johns Hopkins Hospital Emergency Department suggests that federal guidelines for hepatitis C virus (HCV) screening may be missing up to a quarter of all cases and argues for updated universal screening.

15 Apr 2016

AbbVie's ABT-493 and ABT-530 achieve high SVR rates in GT1 chronic HCV patients who failed previous therapy with DAAs

AbbVie, a global biopharmaceutical company, today announced that 91 percent (n=20/22) of genotype 1 (GT1) chronic hepatitis C virus (HCV) infected patients who failed previous therapy with direct-acting antivirals (DAAs) achieved SVR12 with 12 weeks of ABT-493 and ABT-530 with ribavirin (RBV) in the primary intent-to-treat analysis.

15 Apr 2016

VIEKIRAX and EXVIERA achieve high SVR rates in GT1 and GT4 hepatitis C virus infected patients

AbbVie, a global biopharmaceutical company, today announced new real-world data showing 96 percent of genotype 1 (GT1) patients (n=486/505 assessable for analysis) and 100 percent (n=53/53) of genotype 4 (GT4) patients achieved sustained virologic response at 12 weeks post-treatment (SVR12).

15 Apr 2016

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX + EXVIERA

AbbVie, a global biopharmaceutical company, today announced data showing that patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection who received the recommended regimen of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets), with or without ribavirin (RBV), achieved high sustained virologic response rates at 48 weeks post-treatment (SVR48), regardless of the presence of baseline resistance-associated variants (RAVs).

15 Apr 2016

TDF, entecavir duo 'highly effective' for difficult-to-treat chronic HBV

The combination of tenofovir disoproxil fumarate and entecavir induces a high rate of viral suppression in patients with chronic hepatitis B virus infection who have failed multiple nucleos(t)ide analogue regimens, phase IIIb results indicate.

13 Apr 2016

Dynamic HBsAg measurements predict HBV inactivity

In patients with hepatitis B e antigen-negative chronic hepatitis B virus infection, repeated measurement of hepatitis B surface antigen during long-term follow-up can help identify those with inactive virus, suggests a chart review.

13 Apr 2016

HLA-C/KIR genotype linked to HBeAg-positive HBV interferon response

The human leucocyte antigen-C and killer immunoglobin-like receptor genotypes are associated with response to interferon-based therapy in patients with chronic hepatitis B virus infection positive for hepatitis B e antigen, say researchers.

13 Apr 2016

Hepatitis C treatment can be provided safely, effectively within community-based setting

A new study, presented today, demonstrates treatment for Hepatitis C can be provided safely and effectively within a community-based and non-specialist setting. This illustrates the potential for alternative providers to ease pressure on currently overburdened specialists. The study, sponsored by the National Institutes of Health, was presented at The International Liver Congress 2016 in Barcelona, Spain.

13 Apr 2016

HCV patients with hepatocellular carcinoma history could re-develop illness during or after taking DAAs

Data from a new study show that patients with Hepatitis C virus (HCV) taking direct-acting antiviral treatments (DAAs), who have previously fought off hepatocellular carcinoma (HCC), the most common form of liver cancer,1 had a 'high rate' of re-developing their illness.

13 Apr 2016

Studies offer alternative conclusions on efficacy of DAAs for HIV and HCV co-infected patients

Two separate studies presented today at The International Liver Congress 2016 in Barcelona, Spain have offered alternative conclusions regarding the efficacy of direct-acting antivirals (DAAs) among patients co-infected with HIV and Hepatitis C virus (HCV).

13 Apr 2016

Prime boost approach can increase possibility of combined HCV and HIV vaccination

A combined vaccination against Hepatitis C virus (HCV) and HIV moved a step closer, with the results of a study presented at The International Liver Congress 2016 in Barcelona, Spain today.

13 Apr 2016

Study shows 37% of outpatient healthcare staff fail to follow hand hygiene recommendations

Despite having policies in place to prevent infections, staff at outpatient care facilities fail to follow recommendations for hand hygiene 37 percent of the time, and for safe injection practices 33 percent of the time, according to a study published in the April issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology.

12 Apr 2016

Analysis reveals improved survivorship for acute liver failure patients

More patients hospitalized with acute liver failure - often the result of acetaminophen overdose - are surviving, including those who receive a liver transplant and those who don't, an analysis led by a UT Southwestern Medical Center researcher showed.

5 Apr 2016

Inactivation of protein-coding gene promotes liver tissue regeneration in mammals

Scientists at the Children's Medical Center Research Institute at UT Southwestern (CRI) report that inactivating a certain protein-coding gene promotes liver tissue regeneration in mammals.

26 Mar 2016

Lancet experts call for evidence-based approach to drug policy

Fifty years of drug policies aimed at restricting and criminalizing drug use and minor possession have had serious detrimental effects on the health, wellbeing and human rights of drug users and the wider public, according to a major new report by The Lancet and Johns Hopkins University in the US

25 Mar 2016

Hepatitis C News and Research

Latest Hepatitis C News and Research

WFA+-M2BP levels linked to liver fibrosis, HCC progression in chronic HBV

Serum marker may flag liver fibrosis in chronic HBV

Regular aspirin use may help reduce risk of bile duct cancer

New blood treatment technology could reduce malaria risk following blood transfusions

Resolving HBV infection does not reduce liver cancer risk

Johns Hopkins study suggests updated universal screening for hepatitis C virus

AbbVie's ABT-493 and ABT-530 achieve high SVR rates in GT1 chronic HCV patients who failed previous therapy with DAAs

VIEKIRAX and EXVIERA achieve high SVR rates in GT1 and GT4 hepatitis C virus infected patients

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX + EXVIERA

TDF, entecavir duo 'highly effective' for difficult-to-treat chronic HBV

Dynamic HBsAg measurements predict HBV inactivity

HLA-C/KIR genotype linked to HBeAg-positive HBV interferon response

Hepatitis C treatment can be provided safely, effectively within community-based setting

HCV patients with hepatocellular carcinoma history could re-develop illness during or after taking DAAs

Studies offer alternative conclusions on efficacy of DAAs for HIV and HCV co-infected patients

Prime boost approach can increase possibility of combined HCV and HIV vaccination

Study shows 37% of outpatient healthcare staff fail to follow hand hygiene recommendations

Analysis reveals improved survivorship for acute liver failure patients

Inactivation of protein-coding gene promotes liver tissue regeneration in mammals

Lancet experts call for evidence-based approach to drug policy

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Hepatitis C News and Research

Latest Hepatitis C News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in